We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


LabCorp to Accelerate Oncology Research with Thermo Fisher Scientific

LabCorp to Accelerate Oncology Research with Thermo Fisher Scientific content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

LabCorp has announced that it will adopt Thermo Fisher Scientific’s Ion Torrent Genexus System and Oncomine Precision Assay for use in research and development of companion diagnostics as well as other future oncology and precision medicine applications. LabCorp will also evaluate the potential for future deployment of the system and test across its network of laboratories and partner facilities. The adoption is enabled through LabCorp’s participation in Thermo Fisher Scientific’s Next-Generation Sequencing Companion Dx Center of Excellence Program (COEP).

LabCorp will explore a variety of applications for the Genexus System and the Oncomine Precision Assay, in addition to their immediate use for cancer research and the development of new tests. Upon validation, the platform’s automation could be suitable for accelerating access to next-generation sequencing (NGS) testing for clinical trials through LabCorp’s specialty and drug development central laboratories. If cleared or approved for diagnostic use, the system could be made available to smaller LabCorp laboratories, in addition to hospitals and other LabCorp customers, to help expand the reach of efficient, expedient, and cost-effective NGS testing.

Peter Silvester, senior vice president and president of Life Sciences Solutions at Thermo Fisher, said: “Through our valued partnership with LabCorp, we have a pivotal opportunity to expand access to comprehensive genomic profiling. Our goal is to improve the future standard of care by enabling our customers to leverage genomic information in every setting possible.”

The Genexus System is a fully integrated NGS platform that has a turnaround time of 14 hours. It features a specimen-to-report workflow that enables laboratories to scale their sequencing runs for processing small batches of samples economically. Developed for the Genexus System, the Oncomine Precision Assay is a pan-cancer panel that enables comprehensive genomic profiling from formalin-fixed, paraffin-embedded (FFPE) tissue and liquid biopsy samples.

Currently, the Genexus System and Oncomine Precision Assay are being used for research purposes only.